The World Health Organisation’s cancer agency IARC emphasises that “pure” glyphosate also poses carcinogenic and genotoxic risks
Below is an extremely helpful Q&A from the scientists at IARC, the World Health Organisation’s cancer agency.
It resolves questions of whether IARC decided that “pure” glyphosate, as well as the complete herbicide formulations as sold and used, poses a cancer and DNA-damaging risk.
The short answer is: yes. The IARC decided that the formulations are a risk, and so is pure glyphosate.
This shows that attempts to quell public and EU member state concern by tweaking or banning certain co-formulants, like tallowamine, will not get to the root of the glyphosate toxicity problem.
Other vital issues are also covered in the Q&A.
Q&A on Glyphosate
International Agency for Research on Cancer, 1 March 2016
In March 2015, IARC classified glyphosate as “probably carcinogenic to humans” (Group 2A).
This was based on “limited” evidence of cancer in humans (from real-world exposures that actually occurred) and “sufficient” evidence of cancer in experimental animals (from studies of “pure” glyphosate).
IARC also concluded that there was “strong” evidence for genotoxicity, both for “pure” glyphosate and for glyphosate formulations.
The IARC Monographs evaluation is based on the systematic assembly and review of all publicly available and pertinent studies, by independent experts, free from vested interests. It follows strict scientific criteria, and the classification system is recognized and used as a reference all around the world. This is because IARC evaluations are based on independent scientific review and rigorous criteria and procedures.
To reach these conclusions, IARC reviewed about 1000 studies. Some of the studies looked at people exposed through their jobs, such as farmers. Others were experimental studies on cancer and cancer-related effects in experimental systems.
Could the carcinogenic effects of glyphosate be related to the other chemicals in the formulations?
No. The IARC Monographs evaluation is based on the systematic assembly and review of all publicly available evidence relevant to the carcinogenicity of glyphosate. Most people’s exposure to glyphosate concerns commercial formulations that include glyphosate and other ingredients. The Monograph included these studies of real-world exposures to humans. It also included experimental studies of “pure” glyphosate and of glyphosate-based formulations.
For the experimental studies of “pure” glyphosate, the Monograph concluded that the evidence for causing cancer in experimental animals was “sufficient” and the evidence for causing genotoxicity was “strong”. The real-world exposures experienced by human populations are to a variety of formulations of glyphosate with other chemicals, because this is how glyphosate is mainly sold and used. Similar results were reported in studies of different formulations used in different geographical regions at different times.
Taking all of this evidence together, the IARC Working Group classified glyphosate as “probably carcinogenic to humans” (Group 2A). Following the criteria in the Preamble to the IARC Monographs, the classification of glyphosate is based on “limited” evidence of cancer in humans (from exposures that actually occurred) and “sufficient” evidence of cancer in experimental animals (from studies of “pure” glyphosate). This classification is further supported by “strong” evidence for genotoxicity, both for “pure” glyphosate and for glyphosate formulations.
Could the co-formulants be the cause of the genotoxic effects reported in the IARC Monograph?
With regard to genotoxicity, the IARC Working Group evaluated studies of “pure” glyphosate as well as studies of glyphosate-based formulations. The Working Group reached the same hazard conclusion for glyphosate and for its formulations: they concluded that the evidence for genotoxicity was “strong” for glyphosate and “strong” for glyphosate formulations.
Several of the epidemiological studies considered by the IARC expert Working Group showed increased cancer rates in occupational settings after exposure to glyphosate herbicides. Can this be attributed to glyphosate as a single ingredient or could it be due to other chemicals in the formulations?
Real-world exposures that people experience are to glyphosate in formulated products. Studies of humans exposed to different formulations in different regions at different times reported similar increases in the same type of cancer, non-Hodgkin lymphoma. Data on “pure” glyphosate from animal and other experimental studies, including on human cells, support the conclusion from the studies of exposed people. For the studies of “pure” glyphosate, the Monograph concluded that the evidence for cancer in experimental animals was “sufficient” and the evidence for genotoxicity was “strong”.
One of the key studies evaluated in the Monograph was the United States Agricultural Health Study (AHS). This study did not find an association between non-Hodgkin lymphoma and glyphosate. Can this study alone outweigh the positive associations found in other epidemiological studies?
The Agricultural Health Study (AHS) has been described as the “most powerful” study, but this is not correct. The AHS collected data on cancer and pesticide use in more than 50 000 farmers and pesticide applicators in two states in the USA. The weakness of the study is that people were followed up for a short period of time, which means fewer cases of cancer would have had time to appear. This factor can limit the ability of a study to detect an association if one truly exists. Therefore, although the AHS is a large, well-conducted study, its results on glyphosate and non-Hodgkin lymphoma risk do not outweigh those of other studies.
The IARC Working Group also conducted an objective statistical analysis of the results of all of the available studies on glyphosate and non-Hodgkin lymphoma, which included the AHS and all of the case–control studies. The data from all of the studies combined show a statistically significant association between non-Hodgkin lymphoma and exposure to glyphosate.
In the studies IARC evaluated, were there cancers only seen in animals exposed to the toxic doses of glyphosate?
No. The IARC Working Group identified statistically significant trends of higher numbers of cancers with higher doses of “pure” glyphosate in studies of mice, suggesting increasing response with dose. Cancers were seen in the absence of toxicity.
An important consideration in the IARC Working Group’s evaluation was that glyphosate caused unusual types of tumours, which are very rarely seen in untreated animals. Rare tumours can provide important evidence of a cause-and-effect relationship, but may only be seen at high doses. The IARC Working Group’s evaluation of these tumours was in line with accepted principles and gave highly significant results.
Regulatory agencies have reviewed the key studies examined by IARC – and more – and concluded that glyphosate poses no unreasonable risks to humans. What did IARC do differently?
Many regulatory agencies rely primarily on industry data from toxicological studies that are not available in the public domain. In contrast, IARC systematically assembles and evaluates all relevant evidence available in the public domain for independent scientific review.
For the IARC Monograph on glyphosate, the total volume of publications and other information sources considered by the Working Group was about 1000 citations. All citations were then screened for relevance, following the principles in the Preamble to the IARC Monographs.
After this screening process, the Monograph sections on cancer epidemiology and cancer bioassays in laboratory animals cited every included study. The sections on exposure and mechanisms of carcinogenesis consider representative studies and therefore do not necessarily cite every identified study. Once published, the IARC Monograph on glyphosate cited 269 references.
In the interests of transparency, IARC evaluations rely only on data that are in the public domain and available for independent scientific review. The IARC Working Group’s evaluation of glyphosate included any industry studies that met these criteria. However, they did not include data from summary tables in online supplements to published articles, which did not provide enough detail for independent assessment. This was the case with some of the industry studies of cancer in experimental animals.
With the material reviewed by the Working Group, there was enough evidence to conclude that glyphosate is probably carcinogenic to humans.
What does IARC’s classification mean in terms of the probability of developing a cancer?
The IARC Working Group’s classification of glyphosate as “probably carcinogenic to humans” (Group 2A) is based on “limited” evidence of cancer in humans (from real-world exposures that actually occurred) and “sufficient” evidence of cancer in experimental animals (from studies of “pure” glyphosate). This classification is further supported by “strong” evidence for genotoxicity, both for “pure” glyphosate and for glyphosate formulations.
The IARC Monographs evaluation is a hazard classification. It indicates the strength of evidence that glyphosate can cause cancer. The probability of developing a cancer will depend on factors such as the type and extent of exposure and the strength of the effect of the agent.